New agents for treatment of children with acute myelogenous leukemia

Robert J. Wells, Carola A.S. Arndt

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


Over the past 15 years, daunorubicin, cytosine arabinoside and, to a lesser extent, 6-thioguanine and etoposide have become the standard agents used to treat patients with acute myelogenous leukemia (AML). These agents have been used in various combinations and schedules with only small improvements in overall outcome because few other agents with promise were available. This situation has changed over the past few years so that today there are a number of new agents that have the potential to supplement or replace the standard drugs. Idarubicin, mitoxantrone, amsacrine, homoharringtonine, 2-chlorodeoxyadenosine, fludarabine, carboplatin, retinoids, colony stimulating factors, and interleukin-2 are discussed.

Original languageEnglish (US)
Pages (from-to)225-233
Number of pages9
JournalJournal of Pediatric Hematology/Oncology
Issue number3
StatePublished - Aug 1995


  • 2-chloradeoxyadenosine
  • Carboplatin
  • Fludarabine
  • Idarubicin
  • Mitoxantrone

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology


Dive into the research topics of 'New agents for treatment of children with acute myelogenous leukemia'. Together they form a unique fingerprint.

Cite this